STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Deficit
Balance at Feb. 28, 2011	$ (51,255)	$ 131,449	$ 94,260,707	$ (94,443,411)
Balance (in shares) at Feb. 28, 2011		131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.	503,885		503,885
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph. D.	6,663,784		6,663,784
Net loss	(7,157,662)			(7,157,662)
Balance at Feb. 29, 2012	(41,248)	131,449	101,428,376	(101,601,073)
Balance (in shares) at Feb. 29, 2012		131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.	655,182		655,182
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph. D.	5,640,314		5,640,314
Warrants issued for services	159,896		159,896
Net loss	(6,498,806)			(6,498,806)
Balance at Feb. 28, 2013	$ (84,662)	$ 131,449	$ 107,883,768	$ (108,099,879)
Balance (in shares) at Feb. 28, 2013		131,448,444